| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2025-022 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 第三届监事会第十二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 4 月 24 日，奕瑞电子科技集团股份有限公司（以下简称"公司"）以 现场及通讯方式召开了第三届监事会第十二次会议（以下简称"本次会议"），会 议通知已于 2025 年 4 月 11 日以电子邮件形式发出。本次会议由监事会主席丰华 先生主持，会议应出席监事 3 人，实际出席并表决的监事 3 人。本次会议的召开 及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）、《公司章程》 等相关法律法规的规定。 二、监事会会议审议情况 （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 监事会认为：公司《2024 年度监事会工作报告》真实、准确、完整地体现 了公司监事会 202 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2025 年 4 月 24 日，奕瑞电子科技集团股份有限公司（以下简称"公司"）以 现场及通讯方式召开了第三届董事会第十四次会议（以下简称"本次会议"），会 议通知已于 2025 年 4 月 11 日以电子邮件形式发出。本次会议由董事长 Tieer Gu 先生主持，会议应出席董事 8 人，实际出席并表决的董事 8 人。会议的召开及表 决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）、《公司章 程》等相关法律法规的规定。 | 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-021 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 第三届董事会第十四次会议决议公告 二、董事会会议审议情况 （一）审议通过《关于公司<2024 年度董事会工作报告>的议案》 经审议，董事会认为 2024 年度公司董事会在全体董事的共同努力下，根据 《公司法》《公司章程》等规定，本 ...

| 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2025-025 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 奕瑞电子科技集团股份有限公司 关于 2024 年年度利润分配及资本公积转增股本方案 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 分配比例：公司拟向全体股东每 10 股派发现金红利 10.00 元（含税）； 转增比例：公司拟以资本公积向全体股东每 10 股转增 4 股； 本次利润分配及资本公积转增股本以实施权益分派股权登记日登记的总 股本扣减公司回购专用证券账户中的股份为基数，具体日期将在权益分派实施公 告中明确； 在实施权益分派的股权登记日前公司总股本扣除公司回购专用证券账户 中股份基数发生变动的，公司拟维持分配比例、转增比例不变，相应调整分配总 额和转增总额，并将另行公告具体调整情况； 本次利润分配及资本公积转增股本方案已经公司第三届董事会第十四次 会议、第三届监事会第十二次会议审议通过，尚须提交股东大会审议； 本次利润分配及资 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥481,505,741.56, a decrease of 1.92% compared to ¥490,911,525.92 in the same period last year[3] - Net profit attributable to shareholders was ¥143,110,620.86, representing an increase of 2.74% from ¥139,287,790.89 year-on-year[3] - The net profit excluding non-recurring gains and losses was ¥141,283,030.00, down 9.19% from ¥155,573,268.23 in the previous year[3] - Total revenue for Q1 2025 was CNY 481,505,741.56, a decrease of 1.0% from CNY 490,911,525.92 in Q1 2024[17] - Net profit for Q1 2025 was CNY 135,644,940.70, a slight decrease of 1.1% compared to CNY 137,155,894.49 in Q1 2024[18] Earnings and Shares - The basic earnings per share for the period was ¥1.00, up 2.04% from ¥0.98 in the same period last year[3] - The diluted earnings per share was ¥0.96, an increase of 3.23% from ¥0.93 year-on-year[4] - Basic earnings per share for Q1 2025 was CNY 1.00, compared to CNY 0.98 in Q1 2024, reflecting a 2.0% increase[19] Cash Flow - The net cash flow from operating activities was ¥71,178,263.69, a significant improvement from a negative cash flow of ¥42,258,174.73 in the same period last year[3] - Cash flow from operating activities increased significantly to CNY 490,895,984.64 in Q1 2025, up from CNY 344,548,347.08 in Q1 2024, representing a growth of 42.5%[21] - Operating cash inflows totaled $529,645,436.12, compared to $408,229,535.41 in the prior period, showing a year-over-year increase of approximately 29.6%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,133,693,916.40, an increase of 0.56% from ¥9,083,006,463.92 at the end of the previous year[4] - Total liabilities decreased to CNY 4,350,977,177.40 from CNY 4,436,602,437.53, indicating a reduction of 1.9%[16] - The company's total equity increased to CNY 4,782,716,739.00 from CNY 4,646,404,026.39, reflecting a growth of 2.9%[16] Research and Development - Research and development expenses totaled ¥60,088,540.57, a decrease of 12.33% from ¥68,541,759.76 year-on-year, accounting for 12.48% of operating revenue[4] - Research and development expenses for Q1 2025 were CNY 60,088,540.57, down 12.3% from CNY 68,541,759.76 in Q1 2024[18] Government Subsidies - The company received government subsidies amounting to ¥3,145,454.18, which are closely related to its normal operations[6] Current Assets - The company reported a total current assets of approximately ¥3.86 billion as of March 31, 2025, a decrease of about 2.5% from ¥3.95 billion on December 31, 2024[14] - Cash and cash equivalents decreased to approximately ¥1.99 billion from ¥2.10 billion, reflecting a decline of about 5.5%[14] - Accounts receivable increased to approximately ¥769 million, up from ¥749 million, indicating a growth of about 2.5%[14] - Inventory remained relatively stable at approximately ¥794 million, slightly down from ¥798 million[14] Fixed Assets - The company’s fixed assets increased significantly to approximately ¥1.99 billion from ¥1.44 billion, representing a growth of about 38.4%[14] - The company holds long-term equity investments valued at approximately ¥72 million, unchanged from the previous period[14] - The company’s goodwill remained stable at approximately ¥87.78 million[14] - The total non-current assets were approximately ¥2.57 billion, reflecting a decrease from the previous period[14] Shareholder Information - The company has no significant changes in the top ten shareholders or their shareholding status[11] Strategic Developments - There are no significant new strategies or product developments mentioned in the conference call[12]

Dividend and Share Capital - The company plans to distribute a cash dividend of 10.00 RMB per 10 shares, totaling approximately 142.89 million RMB, which represents 30.72% of the net profit attributable to ordinary shareholders [7]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in an increase of 57,155,544 shares, raising the total share capital to 200,218,362 shares [7]. Financial Performance - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the latest quarter [16]. - The company reported a significant increase in revenue, with a year-over-year growth of 15% in Q3 2023, reaching $1.2 billion [19]. - The net profit attributable to shareholders for 2024 was CNY 465,176,804.27, down 23.43% from CNY 607,497,288.52 in 2023 [33]. - The net profit after deducting non-recurring gains and losses for 2024 was CNY 438,536,093.51, a decrease of 25.84% compared to CNY 591,345,651.53 in 2023 [33]. - The company's operating revenue for 2024 was CNY 1,831,395,031.93, a decrease of 1.74% compared to CNY 1,863,788,559.93 in 2023 [33]. - The company achieved operating revenue of 1.831 billion yuan, a year-on-year decrease of 1.74% [200]. - The net profit attributable to the parent company was 465 million yuan, down 23.43% year-on-year [200]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 439 million yuan, a decline of 25.84% year-on-year [200]. Audit and Compliance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy and completeness of the financial report [6]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance [5]. - The company has not reported any instances where more than half of the directors could not guarantee the authenticity of the annual report [10]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties [10]. - The company has not experienced any violations of decision-making procedures regarding external guarantees [10]. - The company has not indicated any special arrangements for corporate governance [9]. Market and User Growth - User data showed a 20% increase in active users, reaching a total of 5 million users [17]. - The company is expanding its market presence in Asia, targeting a 25% increase in market share by the end of 2024 [17]. - The company is exploring strategic acquisitions to enhance its technology portfolio, with a target of $300 million in potential acquisitions [21]. - Market expansion efforts include entering three new international markets, projected to increase market share by 5% [20]. - The company is actively expanding its overseas market presence and deepening cooperation with key clients to increase market share amid softening demand [48]. Research and Development - The company is investing in R&D, allocating 12% of its revenue towards new technology innovations [16]. - The R&D expenditure as a percentage of operating revenue increased to 16.94% in 2024, up 2.85 percentage points from 14.09% in 2023 [35]. - The company achieved a total R&D investment of RMB 310.18 million in the reporting period, accounting for 16.94% of operating revenue, and registered 115 new IPs, including 30 invention patents [49]. - The company has applied for 108 new intellectual property rights during the reporting period, including 30 invention patent applications [159]. - The cumulative total of intellectual property rights registered or authorized by the company has reached 590, including 183 invention patents [160]. - The company is committed to increasing R&D investment to meet market demands and technological trends, ensuring sustainable development [49]. - The company has established a quality management system compliant with international standards, achieving a 100% certification coverage rate for its main production operations [59]. Product Development and Innovation - New product development includes a state-of-the-art digital X-ray imaging system, expected to launch in Q2 2024 [16]. - The introduction of a new imaging solution is anticipated to improve diagnostic accuracy by 30% [17]. - The company successfully launched several new products, including the high-resolution Mercu1717XN detector and the 64-row medical CT detector module, enhancing its product portfolio [49]. - The company has developed advanced digital X-ray detector technologies, mastering six core technology categories, including sensor design and CT detector technology, positioning itself as one of the few global manufacturers with comprehensive core technology capabilities [147]. - The company has achieved mass production sales of micro-focus tubes and has developed various types of X-ray tubes, including dental and CT tubes [73]. - The company has developed several flat panel and line array detectors tailored for different market segments, addressing diverse market needs [134]. Strategic Partnerships and Acquisitions - A strategic acquisition of a competitor was completed, enhancing the company's technology portfolio and expected to contribute an additional $50 million in annual revenue [18]. - The company has established strong partnerships with well-known firms in the medical, dental, and industrial sectors, enhancing its brand recognition and long-term development prospects [117]. - The company is actively pursuing strategic mergers and acquisitions to further enhance its multi-category product offerings and technological capabilities [145]. Operational Efficiency and Cost Management - The company aims to enhance operational efficiency, targeting a 15% reduction in production costs over the next year [18]. - The implementation of AI-driven analytics is expected to improve operational efficiency by 30% [22]. - The company aims to reduce production costs by 15% through the adoption of new manufacturing technologies [19]. - The company has introduced a new supply chain management analysis method, "n+1+2," to optimize inventory levels and production planning [22]. - The company employs a supply chain management model that includes regular meetings to assess customer orders and forecasts, ensuring efficient production planning [75]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, advising investors to be cautious [4]. - The company faces risks related to the concentration of key raw material suppliers, with over 20% of procurement sourced from overseas [182]. - The company is at risk of inventory impairment losses if raw material values decline significantly or if inventory turnover is slow [187]. - The company faces risks related to intellectual property protection and potential technology leaks, which could impact its competitive advantage [178]. - The company is facing risks from potential trade tensions, which could impact sales and competitiveness in overseas markets [194]. Market Trends and Projections - The global medical X-ray imaging equipment market size (excluding CBCT) increased from $21.76 billion in 2015 to $28.71 billion in 2020, with a CAGR of 5.70%, and is projected to reach $47.61 billion by 2030, representing a CAGR of 4.79% from 2021 to 2030 [89]. - The global digital X-ray detector market size is expected to grow from $2.28 billion in 2021 to $5.03 billion by 2030, with a CAGR of 9.3% from 2022 to 2030 [96]. - The global industrial X-ray imaging equipment market is projected to expand significantly, driven by advancements in traditional and new industrial applications [94]. - The global tube market size is estimated at $4.26 billion in 2023, projected to grow to $9.53 billion by 2030, reflecting a CAGR of 12.18% from 2023 to 2030 [100]. - The global combined X-ray source market grew from $1.75 billion in 2017 to $2.39 billion in 2021, with a CAGR of 8.1%, and is expected to reach $7.41 billion by 2030, indicating a CAGR of 14.3% from 2022 to 2030 [101].

奕瑞电子科技集团股份有限公司 内部控制审计报告 2024 年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.co）"进行查测 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.co）"进行查测 ， 立信会计师事务所(特殊普通合伙) DO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP 内部控制审计报告 信会师报字[2025]第 ZA11830 号 奕瑞电子科技集团股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求,我们审计了奕瑞电子科技集团股份有限公司(以下简称贵公 司）2024年12月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定,建立健全和有效实施内部控制,并评 价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的 有效性发表审计意见,并对注意到的非财务报告 ...

奕瑞电子科技集团股份有限公司 审计报告及财务报表 二〇二四年度 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mc.scy.cn） 进行查验 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.sov.cn） 进行查验 奕瑞电子科技集团股份有限公司 审计报告及财务报表 (2024 年 01 月 01 日至 2024 年 12 月 31 日止) | 目录 | 页次 | | --- | --- | | 审计报告 | l -ર | | 财务报表 | | | 合并资产负债表和母公司资产负债表 | 1-4 | | 合并利润表和母公司利润表 | ર-୧ | | 合并现金流量表和母公司现金流量表 | 7-8 | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | 财务报表附注 | 1-126 | 审计报告 信会师报字[2025]第 ZA11829 号 奕瑞电子科技集团股份有限公司全体股东: 一、 审计意见 我们审计了奕瑞电子科技集团股份有限公司(以下简称奕瑞科技) 财务报表,包括 2024 年 12 月 31 日的合并及母公司资产负债 ...

( + T 奕瑞电子科技集团股份有限公司 募集资金年度存放与使用情况 鉴证报告 2024 年度 an Fear FD ロ 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gor.cn）"进行查验 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gor.cn）"进行查鉴 。 奕瑞电子科技集团股份有限公司全体股东: 我们接受委托，对后附的奕瑞电子科技集团股份有限公司（以下 简称"贵公司"）2024年度募集资金存放与使用情况专项报告（以下简 称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 贵公司董事会的责任是按照中国证券监督管理委员会《上市公司 监管指引第2号——上市公司募集资金管理和使用的监管要求（2022 年修订 ）》（证监会公告（2022）15号）、《上海证券交易所科创板 上市公司自律监管指引第1号――规范运作》以及《上海证券交易所 上市公司自律监管指南第1号——公告格式》的相关规定编制募集资 金专项报告。这种责任包括设计、执行和维护与募集资金专项报告编 制相关的内部控制,确保募集资金专项报告真实、准确、完整 ...

关于奕瑞电子科技集团股份有限公司 非经营性资金占用及其他关联资金往来情况 的专项报告 信会师报字[2025]第 ZA11832 号 奕瑞电子科技集团股份有限公司 非经营性资金占用及其他关联资金 往来情况的专项报告 2024 年度 奕瑞电子科技集团股份有限公司全体股东： 我们审计了奕瑞电子科技集团股份有限公司(以下简称"贵公 司")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZA11829 号的 无保留意见审计报告。 贵公司管理层根据中国证券监督管理委员会《上市公司监管指引 第 8 号——上市公司资金往来、对外担保的监管要求》（证监会公告 〔2022〕26 号）和上海证券交易所《科创板上市公司自律监管指南 第 7 号——年度报告相关事项》的相关规定编制了后附的 2024 年度 非经营性资金占用及其他关联资金往来情况汇总表（以下简称"汇总 表"）。 编制汇总表并确保其真实、准确、合法和 ...

奕瑞电子科技集团股份有限公司 截至 2024 年 12 月 31 日止 前次募集资金使用情况报告及鉴证报告 您可使用手机"扫一扫"或进入"注册会计师行业统…监管平台（http://ac.mof.gov.cn】"进行查 您可 录 关于奕瑞电子科技集团股份有限公司 截至2024年12月31日止 前次募集资金使用情况报告的鉴证报告 信会师报字[2025]第ZA11833号 奕瑞电子科技集团股份有限公司全体股东: 我们接受委托,对后附的奕瑞电子科技集团股份有限公司（以下 简称"贵公司"） 截至2024年12月31日止前次募集资金使用情况报告 (以下简称"前次募集资金使用情况报告"）执行了合理保证的鉴证业 务。 一、管理层的责任 贵公司管理层的责任是按照中国证券监督管理委员会《监管规则 适用指引——发行类第7号》的相关规定编制前次募集资金使用情况 报告。这种责任包括设计、执行和维护与前次募集资金使用情况报告 编制相关的内部控制,确保前次募集资金使用情况报告真实、准确、 完整,不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 | | | 页 次 | | --- | --- | --- | | | 前次募集资金 ...